Maurizia Brunetto
A5079697307- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Hepatitis Viruses Studies and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Diet and metabolism studies
- Diabetes and associated disorders
- Monoclonal and Polyclonal Antibodies Research
- Liver physiology and pathology
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Gallbladder and Bile Duct Disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Organ Transplantation Techniques and Outcomes
- Veterinary Medicine and Surgery
- Immunodeficiency and Autoimmune Disorders
- Animal Nutrition and Physiology
- Analytical chemistry methods development
- Cardiovascular Disease and Adiposity
University of Pisa
2016-2025
Azienda Ospedaliera Universitaria Pisana
2016-2025
Institute of Biostructure and Bioimaging
2020-2025
National Research Council
2020-2025
Azienda USL di Bologna
2023
Haydarpaşa Numune Eğitim ve Araştırma Hastanesi
2022
Sağlık Bilimleri Üniversitesi
2022
Center for Disease Analysis
2022
Marmara University
2021
Hospital Privado
2021
Summary. Liver stiffness was measured by transient elastography (FibroScan®) in 228 consecutive patients with chronic viral hepatitis, (115) or without cirrhosis (113), to study its correlations serum transaminases [alanine aminotransferase (ALT)], fibrosis stage and surrogate noninvasive markers of (APRI, FORNS, FibroTest hyaluronic acid). The dynamic profiles liver were compared multiple testing 31 during a 6‐month follow‐up. We identified 8.3 14 kPa as the ≥F2 cut‐offs, respectively:...
Abstract We investigated the relationship between hepatitis B virus surface antigen (HBsAg) serum level decline and posttreatment response in patients with e (HBeAg)-negative chronic from a large multinational study of pegylated interferon alfa-2a (peginterferon alfa-2a), or without lamivudine, versus lamivudine alone. Serum HBsAg was quantified using Architect assay (Abbott Diagnostics) at pretreatment, end treatment (week 48), 6 months after 72) sera 386 537 who participated alfa-2a, 127;...
Hepatitis B virus (HBV) causes chronic infection in more than 350 million people worldwide. It replicates hepatocytes but is non-cytopathic; liver damage thought to be immune mediated. Here, we investigated the role of innate responses mediating patients with HBV infection. Longitudinal analysis revealed a temporal correlation between flares inflammation and fluctuations interleukin (IL)-8, interferon (IFN)-α, natural killer (NK) cell expression tumor necrosis factor–related...
Using an oligonucleotide hybridization assay, we studied the clinical implication of wild-type hepatitis B virus (HBV) and a HBV mutant that is unable to secrete e antigen (HBeAg) because translational defect due stop codon in pre-C region 106 surface antigen-positive patients with chronic B. Wild-type was detected 31 42 (73.8%) HBeAg-positive patients, whereas mixed viral population present 10 (23.8%). Significant differences severity outcome liver disease were not observed two groups...
A regulatory subset of B cells has been found to modulate immune responses in autoimmunity, infection, and cancer, but it not investigated the setting human persistent viral infection. IL-10 is elevated patients with chronic hepatitis virus infection (CHB), its cellular sources impact on antiviral T have addressed. We role pathogenesis CHB. Serum levels were studied longitudinally CHB undergoing spontaneous disease flares. There was a close temporal correlation between fluctuations load or...
Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated chronic B. Bulevirtide inhibits entry HDV into hepatocytes.In this ongoing phase 3 trial, patients D, or without compensated cirrhosis, were randomly assigned, in a 1:1:1 ratio, to receive bulevirtide subcutaneously at 2 mg per day (2-mg group) 10 (10-mg for 144 weeks no treatment 48 followed by 96 (control group). Patients will complete additional follow-up after end treatment. The primary point...